Skip to content
10-Q

Quarterly Report

Foghorn Therapeutics Inc. FHTX

0001628280-25-025312

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 6, 2025 55.74M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $71.31M
Current Liabilities Q1 2025 · Dec 31, 2024 $66.99M
Total Liabilities Q1 2025 · Mar 31, 2025 $320.34M
Total Liabilities Q1 2025 · Dec 31, 2024 $329.51M
Current Assets Q1 2025 · Mar 31, 2025 $225.42M
Current Assets Q1 2025 · Dec 31, 2024 $249.6M
Total Assets Q1 2025 · Mar 31, 2025 $258.69M
Total Assets Q1 2025 · Dec 31, 2024 $283.98M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $55.45M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $79.25M
Shares Diluted Q1 2025 · Mar 31, 2024 42.43M sh
Capex Q1 2025 · Mar 31, 2024 $101K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$29.35M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$97.49M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$77.19M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.59
Eps Basic Q1 2025 · Mar 31, 2024 −$0.59
Sga Expense Q1 2025 · Mar 31, 2024 $7.71M
Rd Expense Q1 2025 · Mar 31, 2024 $25.53M
Net Income Q1 2025 · Mar 31, 2024 −$25.02M
Operating Income Q1 2025 · Mar 31, 2024 −$28.19M
Revenue Q1 2025 · Mar 31, 2024 $5.05M